Bulletin
Investor Alert

New York Markets Open in:

press release

April 26, 2022, 11:44 a.m. EDT

Tiziana Life Sciences to participate in a Fireside Chat At the B. Riley Securities 2022 Virtual Neuro & Ophthalmology Conference

NEW YORK, April 26, Apr 26, 2022 (GLOBE NEWSWIRE via COMTEX) -- NEW YORK, April 26, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd /zigman2/quotes/207307745/composite TLSA -3.97% ("Tiziana" or the "Company"), a clinical-stage biopharmaceutical company developing alternative routes of immunotherapy with a focus on innovative drugs for neurodegenerative diseases, including treatment with intranasal foralumab for Secondary Progressive Multiple Sclerosis, today announced its Chief Executive Officer and Chief Scientific Officer, Kunwar Shailubhai, Ph.D., will participate in a fireside chat at the B. Riley Securities 2022 Virtual Neuro & Ophthalmology Conference on Wednesday, April 27, 2022 at 2:30 p.m. ET (U.S. and Canada) to provide Company updates.

Date: Wednesday, April 27, 2022
Time: 2:30 p.m. Eastern Time (U.S. and Canada)
Webcast: Click this link to access: https://www.webcaster4.com/Webcast/Page/2875/45361

About Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana's innovative intranasal, oral and inhalation approaches in development have the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana's two lead candidates, intranasal foralumab, the only fully human anti-CD3 mAb, and milciclib, a pan-CDK inhibitor, have both demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana's technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.

For further information please contact:Tiziana Life Sciences:Hana Malik, Business Development and Investor Relations Manager
+44 (0) 207 495 2379
email: info@tizianalifesciences.com

United States:
Investors:Irina Koffler
LifeSci Advisors
Tel: (646) 970-4681
ikoffler@lifesciadvisors.com

COMTEX_406269416/2471/2022-04-26T11:44:13

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

(C) Copyright 2022 GlobeNewswire, Inc. All rights reserved.

/zigman2/quotes/207307745/composite
US : U.S.: Nasdaq
$ 0.73
-0.03 -3.97%
Volume: 20,622
Aug. 8, 2022 3:42p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$77.75 million
Rev. per Employee
N/A
loading...

Partner Center

Link to MarketWatch's Slice.